Optune Lua
Novocure, GmbH · Decision date Oct 8, 2025
What did the FDA decide?
FDA records P230042/S004 as a supplement to PMA P230042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 8, 2025.
FDA approval order statement
introduction of a 15 array/box packaging configuration and a 5 array/box packaging configuration, in addition to the currently approved 20 array/box configuration, for the ITE arrays at Novocures contract manufacturer Integra
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Anesthesiology
- Decision date
- Oct 8, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230042/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Novocure, GmbH
- Product code
- SDA
- Decision code
- OK30
- Decision date
- Oct 8, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Electrical tumor treatment fields for non-small cell lung cancer.
- Applicant
- Novocure, GmbH
- Product code
- SDA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230042 · Original PMA
Optune Lua
P230042/S001 · Related supplement
Optune Lua
P230042/S004 received
Application receipt date recorded by FDA.
P230042/S004 · FDA decision
30-Day Notice
P230042/S005 · Related supplement
Optune Lua
P230042/S007 · Related supplement
Optune Lua
P230042/S008 · Related supplement
Optune Lua
P230042/S010 · Related supplement
Optune Lua
Timeline entries are records held by MedtechLedger for P230042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune LuaP230042 | Novocure, GmbH | PMA approval | Oct 15, 2024 | FDA |
Optune LuaP230042/S001 | Novocure, GmbH | PMA supplement | Aug 12, 2025 | FDA |
Optune LuaP230042/S005 | Novocure, GmbH | PMA supplement | Jan 7, 2026 | FDA |
Optune LuaP230042/S007 | Novocure, GmbH | PMA supplement | Feb 25, 2026 | FDA |
Optune LuaP230042/S008 | Novocure, GmbH | PMA supplement | Jul 1, 2026 | FDA |
Optune LuaP230042/S010 | Novocure, GmbH | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P230042/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



